Abstract:The translation of findings from animal models to human disease is a fundamental part in the field of drug development. However, only a small proportion of promising preclinical results in animals translate to human pathophysiology. This underscores the necessity for novel data analysis strategies to accurately evaluate the most suitable animal model for a specific purpose, ensuring cross-species translatability. To address this need, we present In Silico Treatment (IST), a computational method to assess translation of disease-related molecular expression patterns between animal models and humans. By simulating changes observed in animals onto humans, IST provides a holistic picture of how well animal models recapitulate key aspects of human disease, or how treatments transform pathogenic expression patterns to healthy ones. Furthermore, IST highlights particular genes that influence molecular features of pathogenesis or drug mode of action. We demonstrate the potential of IST with three applications using bulk transcriptomics data. First, we assessed two mouse models for idiopathic pulmonary fibrosis (IPF): one involving injury with intra-tubular Bleomycin exposure, and the other Adeno-associated-virus-induced, TGFβ1-mediated tissue transformation (AAV6.2-TGFβ1). Both models exhibited gene expression patterns resembling extracellular matrix derangement in human IPF, whereas differences in VEGF-driven vascularization were observed. Second, we confirmed known features of non-alcoholic steatohepatitis (NASH) mouse models, including choline-deficient, l-amino acid-defined diet (CDAA), carbon tetrachloride hepatotoxicity injury (CCl4) and bile duct ligation surgery (BDL). Overall, the three mouse models recapitulated expression changes related to fibrosis in human NASH, whereas model-specific differences were found in lipid metabolism, inflammation, and apoptosis. Third, we reproduced the strong anti-fibrotic signature and induction of the PPARα signaling observed in the Elafibranor experimental treatment for NASH in the CDAA model. We validated the contribution of known disease-related genes to the findings made with IST in the IPF and NASH applications. The complete data integration IST framework, including an interactive app to integrate and compare datasets, is made available as an open-source R package.

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Risk Assessment of Food Contact Materials II

Computational Systems Toxicology: Emergence, Development and Application

The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD 50 ) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods

In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs

Computational framework for identifying and evaluating mutagenic and xenoestrogenic potential of food additives

Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities

Understanding the Health Implications of Furan and Its Derivatives in Thermally Processed Foods: Occurrence, Toxicology, and Mixture Analysis

Training in modern statistical methodologies and software tools for the definition and analysis of (stochastic) quantitative microbial risk assessment models with a comparison between the Hungarian and Spanish food supply chains

Genotoxicity testing approaches for the safety assessment of substances used in food contact materials prior to their authorization in the European Union

In silico toxicology protocols

Risk-Benefit Assessment of Foods

Using in vitro/in silico data for consumer safety assessment of feed flavoring additives--A feasibility study using piperine

Modelling and magnitude estimation of cross‐contamination in the kitchen for quantitative microbiological risk assessment (QMRA)

In silico toxicology: computational methods for the prediction of chemical toxicity

Comparative case study on NAMs: towards enhancing specific target organ toxicity analysis

In silico approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities

New approach methodologies in human regulatory toxicology - Not if, but how and when!

In Silico Treatment: a computational framework for animal model selection and drug assessment

An in vitro model system for testing chemical effects on microbiome-immune interactions - examples with BPX and PFAS mixtures

The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods